Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

• Status: Completed
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Ghent
• Collaborator: Novartis
• Treatments: Pimecrolimus; Tacrolimus

Criteria

Inclusion Criteria:

• Active or stable vitiligo vulgaris

• lesions at head or neck + maximum 10% lesions at the rest of the body

Exclusion Criteria:

• Topica during last 2 weeks

• Photo(chemo)therapy during last 4 weeks

• Segmentary vitiligo